XVIVO Perfusion – Consensus estimates Q1 2024
XVIVO Perfusion – Consensus estimates Q1 2024
2024-04-19 17:10:00
Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.
Number of contributors: 6 (all of which have been updated or confirmed before the report)
| KPI | Q1 2024E |
| Net sales (MSEK) | 165 |
| Organic growth in local currency (%) | 15.8 |
| Gross profit (MSEK) | 123 |
| EBIT (MSEK) | 9 |
| EBITDA (MSEK) | 26 |
| Net profit (MSEK) | 8 |
| Earnings per share (SEK) | 0.25 |
| Net sales per segment: | |
| Thoracic (MSEK) | 103 |
| Abdominal (MSEK) | 40 |
| Services (MSEK) | 22 |
XVIVO Perfusion’s Q1 report will be released on Wednesday, 24 April, at 07:30 am CEST.